Physician profile
Thomas C Mathew
NPI 1205820321
$13,412.71
in general payments reported to CMS, 2019-2025
31 companies · $845 in 2025
The $845 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,153 · 2020: $1,933 · 2021: $777 · 2022: $975 · 2023: $865 · 2024: $865 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,574.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,765.79 | 2019-2025 | |
| Cardiovascular Systems INC. | $1,365.75 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $1,195.12 | 2019-2025 | |
| Medtronic Vascular, INC. | $870.35 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $519.69 | 2019-2025 | Farxiga, Brilinta |
| Sanofi-Aventis U.S. LLC | $484.10 | 2019-2024 | |
| Amgen INC. | $441.21 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $385.06 | 2021-2024 | Verquvo |
| Kestra Medical Technology Services, INC. | $355.31 | 2024-2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.95 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $227.94 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $139.09 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $135.20 | 2019-2023 | Lifevest |
| Scpharmaceuticals INC. | $129.06 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $126.64 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $125.53 | 2019-2024 | Camzyos |
| Regeneron Healthcare Solutions, INC. | $109.79 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $102.53 | 2023-2024 | Inpefa |
| Abiomed | $101.52 | 2021-2024 | Impella |
| Janssen Pharmaceuticals, INC | $98.63 | 2019-2021 | |
| Chiesi USA, INC. | $92.16 | 2019 | |
| Edwards Lifesciences Corporation | $60.70 | 2020 | |
| Alnylam Pharmaceuticals INC. | $57.97 | 2021-2025 | Onpattro |
| Novo Nordisk INC | $36.11 | 2023-2025 | |
| Astellas Pharma US INC | $30.29 | 2022-2023 | Myrbetriq |
| Cardinal Health 200 LLC | $22.46 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $20.83 | 2022 | |
| Boston Scientific Corporation | $20.72 | 2023 | Watchman Access System |
| Vifor Pharma, INC. | $20.52 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $17.88 | 2023 | Arcalyst |
| Lilly USA, LLC | $17.81 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.